Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory

• Published in: Hereditary cancer in clinical practice 2018-01, Vol.16 (1), p.1-1, Article 1
• Main Authors: Gardner, Sabrina A, Weymouth, Katelyn S, Kelly, Wei S, Bogdanova, Ekaterina, Chen, Wenjie, Lupu, Daniel, Suhl, Joshua, Zeng, Qiandong, Geigenmüller, Ute, Boles, Debbie, Okamoto, Patricia M, McDowell, Geraldine, Hayden, Melissa A, Nagan, Narasimhan
• Format: Article
• Language: English
• Subjects: Cancer genetics; CMMRD; Diagnosis; Diagnostic equipment (Medical); HBOC; Inherited cancer panel; Lynch syndrome; Ovarian cancer; Variant classification; VUS
• ISSN: 1731-2302; 1897-4287; 1897-4287
• DOI: 10.1186/s13053-017-0083-8

Extensive clinical and genetic heterogeneity of inherited cancers has allowed multi-gene panel testing to become an efficient means for identification of patients with an inherited predisposition to a broad spectrum of syndromic and nonsyndromic forms of cancer. This study reports our experience with a 27-gene inherited cancer panel on a cohort of 630 consecutive individuals referred for testing at our laboratory with the following objectives: 1. Determine the rates for positive cases and those with variants of uncertain clinical significance (VUS) relative to data published in the recent literature, 2. Examine heterogeneity among the constituent genes on the panel, and 3. Review test uptake in the cohort relative to other reports describing outcomes for expanded panel testing. Clinical and genomic data were reviewed on 630 individuals tested on a panel of 27 genes selected on the basis of high (≥ 40%) or moderate to low (≤ 40%) lifetime risk of hereditary cancer. These patients were not enriched for adherence to the National Comprehensive Cancer Network (NCCN) criteria for Hereditary Breast and Ovarian Cancer (HBOC) or Lynch Syndrome (LS) and constitute a referral laboratory cohort. Sixty-five individuals with variants classified as pathogenic or likely pathogenic across 14 genes were identified for an overall positive rate of 10.3%. Although a family history of cancer constituted a major reason for referral, accounting for 84% of our cohort, excluding patients with a known familial variant did not have a significant impact on the observed positive rate (9% vs 10.3%). More than half (58%) of the pathogenic or likely pathogenic variants were observed in high or moderate to low risk genes on the panel, while only 42% occurred in classic HBOC or LS-associated genes. These results provide the actual percentage of family or personal history of cancer that can be attributed to pathogenic or likely pathogenic variants in one or more of the genes on our panel and corroborate the utility of multi-gene panels over sequential testing to identify individuals with an inherited predisposition to cancer.